Interim Report – January to March 2015

Non-Regulatory

May 19, 2015

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its its Interim Report for the first quarter 2015.

Financial Highlights

Revenue for the 1st quarter 2015 was SEK 18.9 (9.9) million
Operating result for the period amounted to SEK 2.8 (-2.8) million
EBITDA for the period amounted to SEK 2.9 (-2.7) million
Net result for the period amounted to SEK 2.9 (-3.1) million
Cash flow for the period was SEK -6.0 (-1.8) million
Cash and cash equivalents at the end of the period amounted to SEK 29.9 (31.2) million

Significant events during the quarter

The ongoing work with our proprietary programs have intensified during the period and are developing well
Strong development of revenues during the quarter, mainly driven by a very positive development of royalties
Financial costs have been reduced while the payment terms related to royalties from a product have been extended, thus the underlying cash and cash equivalents at the end of the period amounted to SEK 41.9 (31.2) million

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody^® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Sobi, GE, Daiichi-Sankyo, Daewoong and Thermo Fisher.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.

Further information can be found at: www.affibody.com